Articles tagged with Synucleins
Studies have confirmed that liquid droplets formed by ubiquilin-2 (UBQLN2) facilitate the aggregation and fibril formation of α-synuclein protein. Researchers also discovered a compound that interacts with UBQLN2, preventing its self-association and liquid droplet formation, which may lead to new treatments for neurodegenerative diseases.
Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.
Researchers at Tokyo Medical and Dental University found that mutant α-synuclein protein propagates through the brain's lymphatic system in its monomeric state before aggregating, shedding light on Parkinson's disease progression. The study suggests targeting early events may limit disease progression.
A new study reveals that aggregates of the protein alpha-synuclein spread in the brains of people with Parkinson's disease through a cellular waste-ejection process called lysosomal exocytosis. This process can lead to the deaths of neurons and ultimately result in the characteristic symptoms of the disease.
Researchers from Johns Hopkins Medicine and Dana Farber Cancer Institute found that irisin reduces levels of a protein linked to Parkinson's disease and halts movement problems in mice. Irisin also speeds up the transport and degradation of alpha synuclein via fluid-filled sacs called lysosomes in brain cells.
Researchers at Johns Hopkins Medicine identified a chemical compound that stops the final events in the pathway linked to brain cell death in Parkinson’s disease. The compound, PAANIB-1, blocks the protein parthanatos without affecting its other critical activities, potentially halting neurodegenerative progression.
Researchers at the University of Bath have optimised a peptide that prevents alpha-synuclein misfolding, a key feature of Parkinson's disease. The new molecule, 4654W(N6A), has shown significant promise in lab experiments and could lead to the development of a disease-modifying treatment.
Researchers will investigate hidden signs of brain damage in REM behavior disorder, aiming to identify biomarkers that predict impending neurological disease. The goal is to delay the onset or prevent dementia or Parkinsonism through clinical trials.
Biologist Aleksey Belikov proposes that rapid progression of age-related diseases results from vicious cycles triggered by biochemical reactions. The study highlights the importance of interrupting these cycles in preventing disease progression.
A study published in Science identifies Parthanatos as a key driver of nerve cell degradation in Parkinson's disease. The researchers found that blocking a protein called PARP1 can rescue cells from death, suggesting new targets for drugs to interrupt the disease progression.
Scientists have long debated the structure of alpha synuclein, a protein associated with Parkinson's. A new study models its structure, finding that it can rapidly switch between different conformations. The researchers suggest that stabilizing an ordered structure could prevent aggregation and offer a new drug-design strategy.
Brandeis researchers have produced and determined the structure of alpha-synuclein, a key protein linked to Parkinson's disease. The findings may lead to the development of new treatments by stabilizing the protein.
Researchers have found elevated levels of gamma-synuclein in depressed animals and humans, highlighting its role in regulating neurotransmitters. The study may provide new therapeutic targets for treating depression, which currently has limited effective treatments.
Research suggests that variations in the alpha synuclein gene contribute to alcohol craving in certain individuals. The study found eight SNPs associated with alcohol craving, but not with dependence, indicating a possible subtype of alcoholics influenced by this genetic factor.
Researchers have discovered that synuclein plays a crucial role in communication between neurons, potentially shedding light on the mechanisms underlying Parkinson's and Alzheimer's diseases. The study provides strong evidence that synucleins control the release of neurotransmitters from nerve cells.